Top 10 kidney cancer stories in 2022
As the year comes to a close, we revisit some of this year’s top content on kidney cancer.
There’s been an abundance of news surrounding kidney cancer over the past year. In light of all that has been discovered, Urology Times® is counting down the top pieces of content on kidney cancer in 2022.
10. Dr. Humphrey discusses takeaways from NY GU 2022 in RCC/bladder cancer
Peter A. Humphrey, MD, PhD, provided an overview of important takeaways in bladder and kidney cancer that were discussed at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Watch now.
9. Pembrolizumab/lenvatinib combo shows promise in frontline nccRCC
The combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) showed encouraging antitumor activity as a frontline treatment for patients with non–clear cell renal cell carcinoma, according to preliminary findings from the phase 2 KEYNOTE-B61 trial. Read more.
8. Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma
Kevin Hakimi discussed the background and results of the study, “Interim analysis of PADRES (prior axitinib as a determinant of outcome of renal surgery) clinical trial,” which he presented at the 2022 AUA Annual Meeting. Watch now.
7. Stereotactic ablative radiation effective in systemic therapy–naïve oligometastatic kidney cancer
Stereotactic ablative radiotherapy (SAbR) demonstrated meaningful longitudinal disease control in patients with systemic therapy–naïve oligometastatic renal cell carcinoma (RCC), according to findings from a phase 2 study published in European Urology Oncology. Read more.
6. Questions raised by kidney cancer epidemiology update
Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, discussed the questions raised by the European Urology study, “Epidemiology of Renal Cell Carcinoma: 2022 Update.” Watch now.
5. Novel TKI/immunotherapy combo shows promise in advanced kidney cancer
Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab (Opidvo) showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy, according to findings from a phase 1/2 trial. Read more.
4. Adjuvant pembrolizumab approved in EU for renal call carcinoma
The approval was based on the phase 3 KEYNOTE-564 trial, which showed that at a median follow-up of approximately 24 months, the median disease-free survival was not reached with either adjuvant pembrolizumab or placebo as per investigator assessment. Read more.
3. Dr. Staehler on novel PET imaging agent for kidney cancer
Michael Staehler, MD, discussed early results with 68GA-EMP-100 PET, a novel agent for imaging c-MET expression in renal cell carcinoma. The data were presented at the 2022 AUA annual meeting. Watch now.
2. Dr. Choueiri explains significance of updated adjuvant pembrolizumab in RCC
After FDA approval of pembrolizumab last year, many researchers and clinicians were interested to find out the long-term efficacy of this treatment. Read more.
1. 2022 ASCO GU Lookback: Dr. Kukreja on key kidney and bladder cancer findings
In this video, Janet Kukreja, MD, discussed abstracts on urothelial carcinoma, renal cell carcinoma, and muscle-invasive bladder cancer that were presented at the 2022 Genitourinary Cancers Symposium. Watch now.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.
